Back to top
more

Alcon (ALC)

(Delayed Data from NYSE)

$85.75 USD

85.75
879,016

+0.30 (0.35%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $85.74 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Centene (CNC) Divests Circle Health Group, Optimizes Portfolio

by Zacks Equity Research

Centene (CNC) announces the sale of Circle Health Group to PureHealth in a bid to dispose of non-core assets and grow its core Managed Care business.

Zacks Equity Research

Cigna (CI) Eases Care Delivery With Prior Authorization Removal

by Zacks Equity Research

Cigna's (CI) branch, Cigna Healthcare, lifts the prior authorization requirement on 600-plus medical services, thereby easing administrative burdens and making way for simplified care delivery.

Zacks Equity Research

Has Alcon (ALC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.

Zacks Equity Research

3 Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Zacks Equity Research

Alcon (ALC) Q2 Earnings Surpass Estimates, Margins Increase

by Zacks Equity Research

Alcon (ALC) delivers better-than-expected earnings and revenues in the second quarter of 2023.

Zacks Equity Research

Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Shaun Pruitt headshot

Time to Buy These Medical Stocks as Earnings Approach

by Shaun Pruitt

Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.

Zacks Equity Research

Alcon (ALC) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Alcon (ALC) might have benefitted from the high win rate of Argos Biometer in the second quarter.

Zacks Equity Research

Here's Why You Should Invest in Alcon (ALC) Stock Now

by Zacks Equity Research

Investors are optimistic about Alcon (ALC) owing to its strength in Surgical and Vision Care franchises and upbeat 2023 guidance.

Zacks Equity Research

Zacks Industry Outlook Highlights Alcon, Hologic and Penumbra

by Zacks Equity Research

Alcon, Hologic and Penumbra have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on rising demand for digital health. ALC, HOLX and PEN are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.

Zacks Equity Research

Select Medical (SEM) Expects Q2 Adjusted EBITDA to Jump 21% Y/Y

by Zacks Equity Research

Select Medical's (SEM) strong second-quarter 2023 guidance highlights improving performance in all four segments.

Zacks Equity Research

QIAGEN (QGEN) Expands Digital PCR Offering With New Pact

by Zacks Equity Research

QIAGEN (QGEN) and Niba Labs can assist companies developing cell and gene therapies to overcome significant resource limitations and adhere to stringent project deadlines.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

NextGen (NXGN) Settles Misrepresentation Allegations for $31M

by Zacks Equity Research

NextGen (NXGN) settles accusations of software fraud and anti-kickback violations for $31M. However, the company denies any wrongdoing.

Zacks Equity Research

Alcon (ALC) Gains From Robust Contact Lense Sales, Launches

by Zacks Equity Research

In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on stronger base volume recovery and growth from strategic acquisitions.

Zacks Equity Research

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Zacks Equity Research

Boston Scientific (BSX) Gets FDA Nod for Vercise Software

by Zacks Equity Research

Boston Scientific's (BSX) Vercise Neural Navigator 5 Software has an improved user interface that presents patient data in an easier-to-understand style and enables better therapy delivery.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on strategic acquisitions and robust performance of the DSA and RMS arms.

Zacks Equity Research

Hyperfine (HYPR) ACTION PMR Study Targets Better Stroke Care

by Zacks Equity Research

Hyperfine's (HYPR) ACTION PMR study focuses on utilizing point-of-care brain imaging to identify strokes and salvageable brain tissue.

Zacks Equity Research

Select Medical (SEM) Up 21% Year to Date: More Room to Run?

by Zacks Equity Research

Select Medical (SEM) is well-poised for growth on the back of improved patient volumes, an expanding healthcare portfolio and solid cash-generating abilities.

Zacks Equity Research

Glaukos (GKOS) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

DexCom (DXCM) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Zacks Equity Research

3 Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.